PAG
BIS icon

Private Advisor Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Private Advisor Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,856
Closed -$7K – 1635
2019
Q3 		$7K Buy
+1,856
New +$273K ﹤0.01% 1649
2014
Q4 		– Sell
-16
Closed -$8K – 1022
2014
Q3 		$8K Buy
+16
New +$8.52K ﹤0.01% 1206

Other funds holding BIS

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Private Advisor Group's BIS Position: Q4 2019 in Review

Private Advisor Group sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2019, closing a stake of 1,856 shares — an estimated $7K sold.

Private Advisor Group first reported a position in BIS in Q3 2014 and held it in 2 quarters. The position peaked at $8K in Q3 2014. 8 funds tracked by Wall St. Rank hold BIS as of Q4 2019.

  • Private Advisor Group reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Private Advisor Group sold 1,856 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2019, an estimated $7K.
  • Private Advisor Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2014 and held it in 2 quarters.
  • Private Advisor Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $8K in Q3 2014.
  • 8 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2019.

Based on Private Advisor Group's 13F filing for Q4 2019, filed 10 Feb 2020.